BioCentury
ARTICLE | Company News

Pierre Fabre gets European, African rights to Puma's Nerlynx

April 5, 2019 5:15 PM UTC

Pierre Fabre will pay $60 million up front for commercialization rights to Puma's Nerlynx neratinib in Europe, excluding Russia and Ukraine, and in certain North and West African countries.

Puma Biotechnology Inc. (NASDAQ:PBYI) is also eligible for up to $345 million in milestones from Pierre Fabre Group (Castres, France), plus double-digit royalties...